🩸 Hematology Unveiled

Comprehensive Classification & Clinical Pearls
by Didactic Med

πŸ”΄ Red Blood Cell Disorders

Anemias classified by Mean Corpuscular Volume (MCV)

MICROCYTIC ANEMIAS MCV < 80 fL

πŸ“Š Definition:
Small red blood cells with reduced hemoglobin content
πŸ” Types:
  • Iron Deficiency Anemia: Most common cause worldwide. Low ferritin, high TIBC, low transferrin saturation
  • Thalassemia: Genetic disorder affecting hemoglobin production (Ξ± or Ξ² chains). Target cells on smear
  • Sideroblastic Anemia: Ring sideroblasts in bone marrow. Can be congenital or acquired
  • Lead Poisoning: Basophilic stippling on blood smear. Elevated blood lead levels
  • Anemia of Chronic Disease: Can present as microcytic or normocytic. Elevated ferritin, low TIBC
🎯 Key Labs:
CBC, Iron studies (serum iron, TIBC, ferritin, transferrin saturation), Peripheral smear, Hemoglobin electrophoresis
πŸ’Š Management:
Iron supplementation for IDA, Supportive care for thalassemia, Treat underlying cause
Clinical Pearl: "TAILS" mnemonic for microcytic anemia: Thalassemia, Anemia of chronic disease, Iron deficiency, Lead poisoning, Sideroblastic anemia

NORMOCYTIC ANEMIAS MCV 80-100 fL

πŸ“Š Definition:
Normal-sized RBCs but reduced count. Classify by reticulocyte count
πŸ” Low Reticulocyte Count (Hypoproliferative):
  • Aplastic Anemia: Pancytopenia, hypocellular bone marrow. Can be acquired or inherited (Fanconi)
  • Anemia of Chronic Disease: Inflammation reduces EPO response. Common in CKD, cancer, autoimmune diseases
  • Chronic Kidney Disease: Reduced EPO production. Treat with ESAs
  • Pure Red Cell Aplasia: Selective absence of RBC precursors
  • Myelophthisic Anemia: Bone marrow infiltration (cancer, fibrosis). Teardrop cells on smear
πŸ” High Reticulocyte Count (Hemolytic/Blood Loss):
  • Sickle Cell Disease: HbSS, vaso-occlusive crises. Sickled cells on smear
  • G6PD Deficiency: X-linked, hemolysis with oxidative stress. Bite cells, Heinz bodies
  • Hereditary Spherocytosis: Spherocytes, positive osmotic fragility test. Splenomegaly
  • Autoimmune Hemolytic Anemia: Warm (IgG) or Cold (IgM) antibodies. Positive DAT/Coombs
  • Paroxysmal Nocturnal Hemoglobinuria (PNH): Complement-mediated hemolysis. Flow cytometry for CD55/CD59
  • Microangiopathic Hemolytic Anemia: Schistocytes. Seen in TTP, HUS, DIC, malignant HTN
  • Acute Blood Loss: Trauma, GI bleeding, surgery
🎯 Key Labs:
CBC with reticulocyte count, Peripheral smear, LDH, Haptoglobin, Indirect bilirubin, Direct antiglobulin test (DAT)
Clinical Pearl: Corrected reticulocyte count >2% suggests hemolysis or blood loss. Elevated LDH, low haptoglobin, and elevated indirect bilirubin indicate hemolysis.

MACROCYTIC ANEMIAS MCV > 100 fL

πŸ“Š Definition:
Large red blood cells. Divided into megaloblastic and non-megaloblastic types
πŸ” Megaloblastic (Impaired DNA Synthesis):
  • Vitamin B12 Deficiency: Neurological symptoms (paresthesias, ataxia, dementia). Elevated methylmalonic acid & homocysteine. Causes: pernicious anemia, malabsorption, dietary
  • Folate Deficiency: No neurological symptoms. Elevated homocysteine only. Causes: poor diet, malabsorption, pregnancy, medications (methotrexate, phenytoin)
  • Medications: Methotrexate, hydroxyurea, azathioprine, 5-FU, zidovudine
πŸ” Non-Megaloblastic (Normal DNA Synthesis):
  • Alcoholism: Direct toxic effect on bone marrow. May have concurrent folate deficiency
  • Liver Disease: Impaired lipid metabolism affects RBC membrane. Cirrhosis, hepatitis
  • Hypothyroidism: Reduced EPO production and metabolism
  • Reticulocytosis: Young RBCs are larger (polychromasia)
  • Myelodysplastic Syndrome (MDS): Clonal disorder with dysplastic changes
  • Diamond-Blackfan Anemia: Congenital pure red cell aplasia. Macrocytic with low reticulocytes
🎯 Key Labs:
CBC with MCV, Vitamin B12, Folate, Methylmalonic acid, Homocysteine, Thyroid function, Peripheral smear (hypersegmented neutrophils)
Clinical Pearl: Methylmalonic acid elevated ONLY in B12 deficiency. Homocysteine elevated in BOTH B12 and folate deficiency. Hypersegmented neutrophils (>5 lobes) are pathognomonic for megaloblastic anemia.

βšͺ White Blood Cell Disorders

Leukemias, Myeloproliferative & Myelodysplastic disorders

ACUTE LEUKEMIAS

πŸ” Types:
  • Acute Myeloid Leukemia (AML): >20% myeloblasts in bone marrow. Auer rods. Median age 68 years. FLT3, NPM1, CEBPA mutations
  • Acute Lymphoblastic Leukemia (ALL): >20% lymphoblasts. TdT positive. Philadelphia chromosome (BCR-ABL) in 25% adults. More common in children
  • Acute Promyelocytic Leukemia (APL): AML subtype with t(15;17) PML-RARA. DIC risk. Treat with ATRA + arsenic trioxide
πŸ“Š Presentation:
Pancytopenia, fatigue, infections, bleeding, bone pain, hepatosplenomegaly
πŸ’Š Management:
Induction chemotherapy, consolidation, possible stem cell transplant. APL: ATRA + arsenic

CHRONIC LEUKEMIAS

πŸ” Types:
  • Chronic Myeloid Leukemia (CML): Philadelphia chromosome t(9;22) BCR-ABL fusion. Three phases: chronic, accelerated, blast crisis. Marked leukocytosis with left shift. Massive splenomegaly
  • Chronic Lymphocytic Leukemia (CLL): Most common leukemia in adults. Absolute lymphocytosis >5,000/ΞΌL with smudge cells. Autoimmune hemolytic anemia/ITP common. Richter transformation possible
πŸ’Š Management:
CML: Tyrosine kinase inhibitors (imatinib). CLL: Watch and wait vs chemoimmunotherapy vs targeted therapy (BTK inhibitors, BCL-2 inhibitors)

MYELOPROLIFERATIVE NEOPLASMS (MPN)

πŸ” Types:
  • Polycythemia Vera (PV): ↑RBC mass, JAK2 V617F mutation (95%). Erythromelalgia, pruritis after hot shower. Risk of thrombosis
  • Essential Thrombocythemia (ET): ↑Platelets >450,000. JAK2, CALR, or MPL mutations. Risk of thrombosis and bleeding
  • Primary Myelofibrosis (PMF): Bone marrow fibrosis, teardrop cells, leukoerythroblastic smear. Massive splenomegaly
πŸ’Š Management:
Phlebotomy for PV, Aspirin, Hydroxyurea, JAK2 inhibitors (ruxolitinib) for advanced disease

MYELODYSPLASTIC SYNDROMES (MDS)

πŸ“Š Definition:
Clonal stem cell disorders with ineffective hematopoiesis and dysplasia. Risk of progression to AML
πŸ” Features:
Cytopenias, macrocytosis, dysplastic changes in bone marrow (>10% dysplasia in β‰₯1 lineage), ring sideroblasts may be present
πŸ’Š Management:
Supportive care, growth factors, hypomethylating agents (azacitidine, decitabine), lenalidomide for del(5q), stem cell transplant

🟑 Platelet Disorders

Quantitative and qualitative platelet abnormalities

THROMBOCYTOPENIA (Low Platelets <150,000/ΞΌL)

πŸ” Decreased Production:
  • Bone Marrow Failure: Aplastic anemia, MDS, leukemia, metastatic cancer
  • Nutritional: B12, folate deficiency
  • Medications: Chemotherapy, alcohol
πŸ” Increased Destruction:
  • Immune Thrombocytopenic Purpura (ITP): Isolated thrombocytopenia, antiplatelet antibodies. First-line: corticosteroids, IVIG
  • Thrombotic Thrombocytopenic Purpura (TTP): Pentad: thrombocytopenia, MAHA, fever, renal dysfunction, neurologic changes. ADAMTS13 deficiency. Emergency: plasma exchange
  • Hemolytic Uremic Syndrome (HUS): Triad: MAHA, thrombocytopenia, acute kidney injury. Often post-diarrheal (E. coli O157:H7)
  • Heparin-Induced Thrombocytopenia (HIT): Paradoxical thrombosis. Stop heparin, start direct thrombin inhibitor
  • DIC: Consumption coagulopathy. ↓Platelets, ↓Fibrinogen, ↑PT/PTT, ↑D-dimer
πŸ” Sequestration:
Hypersplenism (cirrhosis, portal hypertension)
πŸ” Dilutional:
Massive transfusion

THROMBOCYTOSIS (High Platelets >450,000/ΞΌL)

πŸ” Primary (Clonal):
  • Essential Thrombocythemia: JAK2, CALR, or MPL mutations. Risk of thrombosis and bleeding
  • Polycythemia Vera, CML, PMF: Can present with elevated platelets
πŸ” Secondary (Reactive):
Inflammation, infection, iron deficiency, malignancy, splenectomy, acute bleeding, recovery from bone marrow suppression

PLATELET FUNCTION DISORDERS

πŸ” Types:
  • Bernard-Soulier Syndrome: Giant platelets, deficiency of GPIb-IX-V complex
  • Glanzmann Thrombasthenia: Deficiency of GPIIb-IIIa complex
  • Storage Pool Defects: Dense granule or Ξ±-granule deficiency
  • Acquired: Uremia, medications (aspirin, NSAIDs, clopidogrel), myeloproliferative disorders
πŸ“Š Presentation:
Mucocutaneous bleeding, prolonged bleeding time, normal platelet count, abnormal platelet aggregation studies

🟣 Coagulation Disorders

Bleeding and thrombotic disorders

HEMOPHILIA

πŸ” Types:
  • Hemophilia A: Factor VIII deficiency. X-linked recessive. Most common severe bleeding disorder
  • Hemophilia B (Christmas Disease): Factor IX deficiency. X-linked recessive
πŸ“Š Labs:
Prolonged PTT, normal PT, normal platelets, decreased factor VIII or IX levels
πŸ“Š Presentation:
Hemarthrosis, deep tissue bleeding, intracranial hemorrhage, excessive bleeding with surgery/trauma
πŸ’Š Management:
Factor replacement (recombinant or plasma-derived), desmopressin for mild hemophilia A, emicizumab for hemophilia A with inhibitors

VON WILLEBRAND DISEASE (VWD)

πŸ“Š Definition:
Most common inherited bleeding disorder. Deficiency or dysfunction of von Willebrand factor (vWF)
πŸ” Types:
  • Type 1 (75%): Partial quantitative deficiency. Autosomal dominant
  • Type 2: Qualitative defects in vWF. Multiple subtypes (2A, 2B, 2M, 2N)
  • Type 3 (Rare): Complete deficiency. Autosomal recessive. Severe bleeding
πŸ“Š Labs:
Low vWF antigen, low vWF activity (ristocetin cofactor), may have prolonged PTT, may have low Factor VIII
πŸ’Š Management:
Desmopressin (DDAVP) for type 1, vWF/Factor VIII concentrates, antifibrinolytics (tranexamic acid)

OTHER COAGULATION DISORDERS

πŸ” Bleeding Disorders:
  • Factor XI Deficiency: Mild bleeding, common in Ashkenazi Jews. Prolonged PTT
  • Vitamin K Deficiency: ↓Factors II, VII, IX, X. Prolonged PT and PTT. Causes: malabsorption, antibiotics, warfarin
  • Liver Disease: Decreased synthesis of all clotting factors. Prolonged PT/PTT, low platelets
  • DIC: Consumption of clotting factors and platelets. ↓Fibrinogen, ↑PT/PTT, ↑D-dimer, schistocytes
πŸ” Thrombotic Disorders:
  • Factor V Leiden: Most common inherited thrombophilia. Resistance to activated protein C
  • Prothrombin G20210A Mutation: Elevated prothrombin levels
  • Protein C/S Deficiency: Autosomal dominant. Warfarin-induced skin necrosis risk
  • Antithrombin Deficiency: Most severe thrombophilia. Heparin resistance
  • Antiphospholipid Syndrome: Lupus anticoagulant, anticardiolipin antibodies. Paradoxical thrombosis with prolonged PTT

🟒 Other Hematologic Disorders

Lymphomas, Plasma Cell disorders, and other conditions

LYMPHOMAS

πŸ” Hodgkin Lymphoma:
  • Classic Hodgkin: Reed-Sternberg cells required. B symptoms common (fever, night sweats, weight loss)
  • Subtypes: Nodular sclerosis (most common, young females), Mixed cellularity, Lymphocyte-rich, Lymphocyte-depleted
  • Staging: Ann Arbor staging system. Favorable prognosis with ABVD chemotherapy Β± radiation
πŸ” Non-Hodgkin Lymphoma:
  • Diffuse Large B-Cell Lymphoma (DLBCL): Most common NHL. Aggressive, rapidly growing mass. R-CHOP chemotherapy
  • Follicular Lymphoma: Indolent, t(14;18) BCL2 translocation. Watch and wait vs treatment
  • Mantle Cell Lymphoma: t(11;14) Cyclin D1. Intermediate prognosis
  • Marginal Zone Lymphoma: MALT lymphoma. Associated with H. pylori (gastric)
  • Burkitt Lymphoma: Highly aggressive, "starry sky" appearance, c-myc translocation, associated with EBV
  • Peripheral T-Cell Lymphomas: Heterogeneous group, generally poor prognosis
πŸ“Š Diagnosis:
Lymph node biopsy with immunohistochemistry and flow cytometry, PET/CT for staging

PLASMA CELL DISORDERS

πŸ” Multiple Myeloma:
  • Definition: Clonal plasma cell proliferation >10% in bone marrow with end-organ damage
  • CRAB Criteria: Calcium elevated, Renal insufficiency, Anemia, Bone lesions
  • Labs: Monoclonal protein (M-spike) on SPEP/UPEP, elevated free light chains, Bence Jones proteinuria
  • Imaging: Lytic bone lesions on skeletal survey or whole-body CT
  • Treatment: Induction therapy (bortezomib, lenalidomide, dexamethasone) Β± autologous stem cell transplant
πŸ” MGUS:
Monoclonal gammopathy of undetermined significance. M-protein <3 g/dL, <10% plasma cells, no end-organ damage. 1% annual risk of progression to myeloma
πŸ” WaldenstrΓΆm Macroglobulinemia:
Lymphoplasmacytic lymphoma with IgM monoclonal protein. Hyperviscosity syndrome possible. MYD88 L265P mutation
πŸ” Amyloidosis (AL):
Clonal plasma cells produce light chains that deposit as amyloid. Affects heart, kidneys, nerves. Congo red stain shows apple-green birefringence

MISCELLANEOUS DISORDERS

πŸ” Hemochromatosis:
Iron overload disorder. HFE gene (C282Y). Bronze diabetes: skin hyperpigmentation, diabetes, hepatomegaly, cardiomyopathy. High ferritin, high transferrin saturation. Treatment: phlebotomy
πŸ” Porphyrias:
Heme synthesis defects. Acute intermittent porphyria: abdominal pain, neuropsychiatric symptoms. Porphyria cutanea tarda: photosensitivity, blistering
πŸ” Methemoglobinemia:
Oxidized hemoglobin (Fe³⁺) cannot carry oxygen. Cyanosis with normal PaOβ‚‚. Chocolate-colored blood. Causes: dapsone, nitrates, benzocaine. Treatment: methylene blue
πŸ” Hemoglobinopathies:
  • Sickle Cell Disease: HbSS, vaso-occlusive crises, splenic sequestration, acute chest syndrome
  • Hemoglobin C Disease: Mild hemolytic anemia, target cells
  • Hemoglobin E: Common in Southeast Asia, mild microcytic anemia
πŸ“š Evidence-Based Guidelines Referenced:
  • WHO Classification of Haematolymphoid Tumours (5th Edition, 2022)
  • American Society of Hematology (ASH) Clinical Practice Guidelines 2024-2025
  • International Consensus Classification of Myeloid Neoplasms (2022)
  • National Comprehensive Cancer Network (NCCN) Guidelines 2024
  • British Society for Haematology Guidelines